All about COVID-19

Coronavirus | Why people with prior infection still need COVID-19 vaccination

Protection level: Asymptomatic infections may result in low antibody levels or even no antibodies being measured in up to 20% of people.   | Photo Credit: zoranm

As on January 1, nearly 10.3 million SARS-CoV-2 cases have been reported in India, and in all about 50% of people in large urban cities and about 30% of those across India would have already been infected. The four high-risk groups that would receive the vaccine on priority in India alone amount to 300 million people, meaning 600 million doses would be required to vaccinate them.

Since vaccine shortage is expected to last at least for a few months, it may seem appealing to delay or avoid vaccinating those who have been naturally infected. But does science support such a decision?

“A small minority of those with even symptomatic infection do not end up making high levels of antibodies, and another small minority of such naturally infected people do not make long-lasting antibodies. So, all in all, it is the easiest policy to immunise people without worrying about whether they have been previously infected or not,” immunologist Dr. Satyajit Rath, formerly with the Delhi-based National Institute of Immunology, says in an email.

Dr. Gagandeep Kang, Professor of Microbiology at CMC Vellore elaborates saying that while highest levels of binding antibodies are seen in people with the most severe disease, asymptomatic infections may result in low antibody levels or even no antibodies being measured in up to 20% of people.

Watch | Can people contract COVID-19 after inoculation?

Besides binding antibodies, functional antibodies that block or neutralise the virus are also found in infected people. “Limited studies patients indicate that memory T cells are produced against the virus which indirectly implies that immunity is likely to be longer,” says neurovirologist Dr. V. Ravi formerly with NIMHANS.

Lack of knowledge

“At the moment, we do not know what really protects against SARS-CoV2 disease, and at what threshold, and for how long. Vaccines are made to induce a good immune response, which is expected to be more predictable than the response to infection. But immune responses in vaccinated people are still being studied, particularly to understand what is protective and how long protection lasts,” says Dr. Kang in an email. “Based on all that we know and do not know at this time, it is advised that even if you have been infected before, you should take the vaccine.”

“Both practical considerations as well as lack of precise information on how long immunity lasts after a natural infection necessitates that we do not discriminate against people, says Dr. Ravi.

Another reason why skipping vaccination in people already infected might not be advisable is the way the virus in general primes the immune system. Dr. Rath says immune responses to natural infection can be modified by immune evasion mechanisms of the virus. But vaccine formulations do not include those viral tricks, and therefore, immune responses to the vaccines are more likely to be uniform and predictable. “Yes, it is possible that vaccines can result in an immune response that does better than natural infection. We have known this for a long time,” adds Dr. Kang.

Variable responses

Like in the case of natural infection, vaccines too can produce responses that can be variable across people. “Virus dosage varies a great deal in natural infection, and viral immune evasion tricks work variably well in different individuals. These two sources of variation do not apply to vaccines, so variation in vaccine-generated immune responses is likely to be less than that in natural infection,” Dr. Rath explains. Dr. Ravi says that variation will depend on the type of vaccine, host age and underlying comorbidities, which generally can cause a degree of immunosuppression.

Globally, only a handful of reinfection cases have been documented so far, and a few studies show that protection from natural infection lasts over six months. Despite overwhelming evidence, it does not support skipping vaccination in those with prior infection. First, there is no evidence for how long on average protection from natural infection lasts. Also, large-scale genome sequencing studies have not been undertaken to categorically say reinfections have been just a handful.

Challenging prospect

“In principle, if infection protects against sufficient disease, it would be okay for people who have measurable protection to wait to be vaccinated. But since we do not know how long protection lasts, what constitutes a measure of protection and the logistics of getting people in priority groups back when the period of protection has waned, I think it would be challenging to establish a system that denies vaccination to those recently infected, even for a limited time,” emphasises Dr. Kang.

Another possible reason to avoid vaccinating people with prior infection is the possibility of disease exacerbation. But there is no such evidence in the case of coronavirus. For one, some phase-3 trials have not tested participants for pre-existing antibodies prior to vaccination and excluded them. And so far, there are no reports of any harm, although it is not clear if the evidence is large enough to be sure. “There is no reason to assume that we should expect a problem. Unlike dengue where this may be an issue, we do not have multiple types of viruses causing COVID-19,” she says.

If vaccination is to be done selectively, the bigger issue is of testing people for antibodies prior to vaccination. This raises several challenges — increased cost and time, logistics and manpower. “It is not really possible to operationalise pre-vaccination testing on a routine basis. We’re already learning in the U.S. that vaccinating the nation is a complicated undertaking and keeping it as simple as possible without complicated or fussy criteria might become necessary,” Dr. Peter Hotez, Professor, Departments of Pediatrics, Molecular Virology & Microbiology, Baylor College of Medicine says in an email.

Also, since antibodies wane in about six months, ascertaining the infection status in people who were infected early during the pandemic becomes even more challenging and unlikely to give answers that are of practical use or public health solution.

Our code of editorial values

Related Topics
This article is closed for comments.
Please Email the Editor

Printable version | Jan 24, 2022 8:29:54 PM |

In This Package
The Hindu Explains | How is India preparing to roll out COVID-19 vaccines?
The Hindu Explains | Why was a COVID-19 vaccine dry run necessary, and how was it organised?
You are reading
Coronavirus | Why people with prior infection still need COVID-19 vaccination
Explained | What we know about China-made vaccines
How infections among participants are a part of vaccine trials | The Hindu In Focus podcast
The Hindu Explains | What is emergency use authorisation for drugs and vaccines?
Coronavirus | How the new variant quickly accumulated 23 mutations
Coronavirus | New variant does not increase reinfection risk, disease severity, deaths
Coronavirus | N501Y mutation in SARS-CoV-2 virus causes increased infectivity in mice: researchers
The Hindu Explains | Are viruses expected to change form, and will vaccines protect against a mutating SARS-CoV-2?
Coronavirus | Is the first wave coming to an end in India?
Has India passed the COVID-19 peak? | The Hindu Parley podcast
Has India passed its COVID-19 peak, as a new government study claims? | The Hindu In Focus podcast
No evidence to suggest coronavirus cluster 5 variant found in minks increases virus transmissibility, disease severity
SARS-CoV-2 not the last virus to spark a pandemic, says expert
The Hindu Explains | Who are the top contenders in the race for a COVID-19 vaccine?
The vaccine networks India will rely on and the challenges ahead | The Hindu In Focus podcast
Study advances use of indomethacin for treatment of mild cases
How an asymptomatic player turned super-spreader
How close are we to getting a COVID-19 vaccine? | The Hindu In Focus podcast
WHO warns against pursuing herd immunity to stop coronavirus
Studies document in-flight transmission of coronavirus
Experimental study finds how coronavirus can spread while speaking
Can universal masking be a crude ‘vaccine’?
The Hindu Explains | Is COVID-19 setting off a bradykinin storm in the body?
Coronavirus | Lung damage in COVID-19 dead may shed light on ‘long COVID’: study
The Hindu Explains | What does herd immunity mean for COVID-19?
The Hindu Explains | What do we know about Russia’s COVID-19 vaccine candidate Sputnik V?
Coronavirus | Russian vaccine generated strong immune response, says Lancet study
Watch | Is COVID-19 intensifying in rural India?
The Hindu Explains | Why is Phase-3 of COVID-19 vaccine trial complicated?
The Hindu Explains | What are the long-term effects of COVID-19?
The Hindu Explains | Are there re-infection fears around COVID-19?
Watch | COVID-19 and children
The Hindu Explains | Is SARS-CoV-2 a latent virus which can recur?
Watch | What is an immunity passport?
WHO says COVID-19 by far its worst global health emergency
CDC says revised guidance on coronavirus spread posted in error, removes it
Coronavirus | Plasma therapy may look promising in treating COVID-19, but it is no magic bullet
Coronavirus | Different kinds of SARS-CoV-2 exist in India but none more lethal than the other: Indian Academy of Sciences President
The Hindu Explains | Is airborne transmission of COVID-19 a risk?
Watch | What are serological surveys?
The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients?
Video: In conversation with Andrew Pollard, Director of Oxford Vaccine Group
Watch | All you need to know about pulse oximeters
Coronavirus | Why are only a fraction of cases tested?
Coronavirus | Vaccine was rapidly synthesised as novel coronavirus sequence was available, says virologist Gagandeep Kang
A step closer to developing a potent drug against novel coronavirus
Coronavirus | The importance of ‘contact tracing’
Coronavirus | Are diabetics more prone to COVID-19?
Private firms ready to test for COVID-19
Coronavirus | How does soap use help in tackling COVID-19?
Fight for the finite: On budgetary allocation for health
Coronavirus | A problematic testing strategy
Fighting COVID-19 together for a shared future
Scientists get ready to test rival COVID-19 pandemic vaccines in animals
Coronavirus | The cost of opacity
Watch | COVID-19: Masks and sanitisers are now essential commodities
A COVID-19 control plan made simple
Watch | Your COVID-19 queries answered
Coronavirus | How is India containing COVID-19?
Battle against COVID-19
Watch | COVID-19: Dos and don'ts from the Health Ministry
A COVID-19 response that is quick off the blocks
Watch | Why is COVID-19 not a pandemic yet?
Watch | Coronavirus: Can masks protect you?
Watch | How is India dealing with coronavirus?
WHO’s unexplained hesitancy
Watch | Bats and the novel coronavirus
Coronavirus | India shares two SARS-CoV-2 genome sequences
COVID-19 | We are in uncharted territory, says WHO
Explained | Why is COVID-19 not a pandemic yet?
New COVID-19 epidemic at ‘decisive point’: WHO chief
COVID-19 vaccine may be ready by 2022: SII
Explainer: How WHO names a new disease
WHO names deadly viral disease from China as 'COVID-19'
Explained | When can people transmit the novel coronavirus?
Analysis | For China’s Xi, the coronavirus challenge comes laden with economic costs and political risks
How bats harbour several viruses yet not get sick
WHO declares coronavirus outbreak a global emergency
Watch | What is Coronavirus?
What is the source of the new SARS-like disease reported in China?
Data | The wide, rapid spread of the novel coronavirus
Alarming spread: on novel coronavirus outbreak
Gaps in our knowledge of coronavirus origin need fulfilment: Study
A new virus emerges in China
Next Story